Raymond Chung
Professor of Medicine at Harvard Medical School
Biography
Harvard Medical School
Raymond Chung, MD, is Director of Hepatology and the Liver Center at Massachusetts General Hospital, Vice Chief of Gastroenterology, and Kevin and Polly Maroni MGH Research Scholar. In 2021, he will serve as President of the American Association for the Study of Liver Diseases. Dr. Chung completed his B.A. at Harvard College and his MD from Yale University School of Medicine. He completed a residency in Internal Medicine at Johns Hopkins and a fellowship in Gastroenterology and Hepatology at Massachusetts General Hospital.
Dr. Chung has been internationally recognized for his fundamental and translational research in viral hepatitis, particularly in HCV and HBV infection. His laboratory has elucidated the basis for the observed accelerated liver disease pathogenesis in persons with HIV. He has also led important work defining biomarkers and gene signatures for persons at high risk for liver disease progression and liver cancer, and designed therapeutic studies to prevent this progression.
Departments, Centers, & Programs:
- Cancer Center
- Gastrointestinal Cancers
- Liver Cancer
- Digestive Healthcare Center
- Colorectal Center
- Transplant Center
- Liver Transplant
- Gastroenterology
Clinical Interests:
- Autoimmune hepatitis, Autoimmune liver disease
- Hepatitis B virus (HBV)
- Hepatitis C virus (HCV)
- Liver cancer
- Liver disease / Hepatology
- Liver transplant
- Non-alcoholic fatty liver disease
Medical Education
- MD, Yale University School of Medicine
- Residency, Johns Hopkins Hospital
- Fellowship, Massachusetts General Hospital
American Board Certifications
- Gastroenterology, American Board of Internal Medicine
- Internal Medicine, American Board of Internal Medicine
- Transplant Hepatology, American Board of Internal Medicine
Publications
- Simon TG, Ma Y, Ludvigsson JF, Chong DQ, Giovannucci EL, Fuchs CS, Meyerhardt JA, Corey KE, Chung RT, Zhang X, Chan AT. Association Between Aspirin Use and Risk of Hepatocellular Carcinoma. JAMA Oncol 2018. PubMed
- Bhan I, Mosesso K, Goyal L, Philipp J, Kalinich M, Franses JW, Choz M, Oklu R, Toner M, Maheswaran S, Haber DA, Zhu AX, Chung RT, Aryee M, Ting DT. Detection and Analysis of Circulating Epithelial Cells in Liquid Biopsies From Patients With Liver Disease. Gastroenterology 2018. PubMed
- Liu X, Duan X, Holmes JA, Li W, Lee SH, Tu Z, Zhu C, Salloum S, Lidofsky A, Schaefer EA, Dachuan C, Li S, Wang H, Huang Y, Zhao Y, Yu ML, Xu Z, Chen L, Hong J, Lin W, Chung RT. A novel lncRNA regulates HCV infection through IFI6. Hepatology 2018. PubMed
- Bethea ED, Samur S, Kanwal F, Ayer T, Hur C, Roberts MS, Terrault N, Chung RT, Chhatwal J. Cost-effectiveness of Transplanting HCV-Infected Livers into Uninfected Recipients with Preemptive Antiviral Therapy. Clin Gastroenterol Hepatol 2018. PubMed
- Lidofsky A, Holmes JA, Feeney ER, Kruger AJ, Salloum S, Zheng H, Seguin IS, Altinbas A, Masia R, Corey KE, Gustafson JL, Schaefer EA, Hunt PW, Deeks S, Somsouk M, Chew KW, Chung RT, Alatrakchi N. Macrophage Activation Marker Soluble CD163 is a Dynamic Marker of Liver Fibrogenesis in HIV/HCV Coinfection. J Infect Dis 2018. PubMed
- Kruger AJ, Fuchs BC, Masia R, Holmes JA, Salloum S, Sojoodi M, Ferreira DS, Rutledge SM, Caravan P, Alatrakchi N, Vig P, Lefebvre E, Chung RT. Prolonged cenicriviroc therapy reduces hepatic fibrosis despite steatohepatitis in a diet-induced mouse model of nonalcoholic steatohepatitis. Hepatol Commun 2018; 2:529-545. PubMed
- Duan X, Li S, Holmes JA, Tu Z, Li Y, Cai D, Liu X, Li W, Yang C, Jiao B, Schaefer EA, Fusco DN, Salloum S, Chen L, Lin W, Chung RT. MicroRNA 130a Regulates both Hepatitis C Virus and Hepatitis B Virus Replication through a Central Metabolic Pathway. J Virol 2018. PubMed
- Khalili M, Shuhart MC, Lombardero M, Feld JJ, Kleiner DE, Chung RT, Terrault NA, Lisker-Melman M, Sanyal A, Lok AS, . Relationship Between Metabolic Syndrome, Alanine Aminotransferase Levels, and Liver Disease Severity in a Multiethnic North American Cohort With Chronic Hepatitis B. Diabetes Care 2018. PubMed
- Qu C, Zheng D, Li S, Liu Y, Lidofsky A, Holmes JA, Chen J, He L, Wei L, Liao Y, Yuan H, Jin Q, Lin Z, Hu Q, Jiang Y, Tu M, Chen X, Li W, Lin W, Fuchs BC, Chung RT, Hong J. Tyrosine Kinase SYK is a Potential Therapeutic Target for Liver Fibrosis. Hepatology 2018. PubMed
- Bethea E, Chen Q, Hur C, Chung RT, Chhatwal J. Response to Treatment of Acute HCV Cost-Effective but at What Price? Hepatology 2018. PubMed
- Fusco DN, Ganova-Raeva L, Khudyakov Y, Punkova L, Mohamed A, Cheon SSY, Koirala P, Andersson KL, Jourdain G, Sureau C, Chung RT, Lauer G. Reactivation of a Vaccine Escape Hepatitis B Virus Mutant in a Cambodian Patient During Anti-Hepatitis C Virus Therapy. Front Med (Lausanne) 2018; 5:97. PubMed
Videos
HCV: Arc of a medical triumph
2021 Welcome Message from AASLD President, Raymond T. Chung, MD, FAASLD
4/16/2021: Hepatitis C Virus: Remaining Challenges
Read about executive education
Other experts
Looking for an expert?
Contact us and we'll find the best option for you.